Research Article

Immunological detection of pyrazine-2-carboxylic acid for the detection of pyrazinamide resistance in *Mycobacterium tuberculosis*

Edgar A. Florentini¹, Noelia Angulo¹, Robert H. Gilman², Roberto Alcántara¹, Elisa Roncal¹, Ricardo Antiparra¹, Emily Toscano¹, Katherine Vallejos¹, Danni Kirwan¹, Mirko Zimic¹, Patricia Sheen¹*¹

¹ Laboratorio de Bioinformática y Biología Molecular, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, San Martín de Porras, Lima, Perú
² Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America

*patricia.sheen@upch.pe

Abstract

Pyrazinamide (PZA) susceptibility testing in *Mycobacterium tuberculosis* (Mt) is a current area of development and PZA-resistant strains are increasingly prevalent. Previous studies have demonstrated that the detection of pyrazinoic acid (POA), the metabolite produced by the deamination of PZA, is a good predictor for PZA resistance since a resistant strain would not convert PZA into POA at a critical required rate, whereas a susceptible strain will do, expelling POA to the extracellular environment at a certain rate, and allowing for quantification of this accumulated analyte. In order to quantify POA, an indirect competitive ELISA (icELISA) test using hyperimmune polyclonal rabbit serum against POA was developed: for this purpose, pure POA was first covalently linked to the highly immunogenic Keyhole Limpet Hemocyanine, and inoculated in rabbits. A construct made of bovine serum albumin (BSA) linked to pure POA and fixed at the bottom of wells was used as a competitor against spiked samples and liquid Mt culture supernatants. When spiked samples (commercial POA alone) were analyzed, the half maximal inhibitory concentration (IC50) was 1.16 mg/mL, the limit of detection 200 μg/mL and the assay was specific (it did not detect PZA, IC50 > 20 mg/mL). However, culture supernatants (7H9-OADC-PANTA medium) disrupted the competition and a proper icELISA curve was not obtainable. We consider that, although we have shown that it is feasible to induce antibodies against POA, matrix effects could damage its analytical usefulness; multiple, upcoming ways to solve this obstacle are suggested.

Introduction

Tuberculosis (TB) is the leading infectious cause of morbidity and mortality worldwide. In 2017, approximately 1.3 million deaths and 10 million new cases were reported [1]. During this period 3.5% of new TB cases and 18% of previously treated cases were reported as having...
multi-drug resistance (MDR-TB) [1], with low and middle-income countries impacted the most [2].

Pyrazinamide (PZA) is a drug that has been used to treat TB since 1952 [3], and is presently included in both first- and second-line regimens [4]. Currently, the prevalence of PZA resistance is not well known. However, high rates of mortality have been reported when PZA is administered empirically to patients who are infected with PZA-resistant strains [5]. PZA resistance is associated with resistance to other TB medications: current estimates indicate that 50% of MDR-TB cases are also PZA resistant [6–8] and, alarmingly, the emergence of *Mycobacterium tuberculosis* (Mtbc) strains resistant to all known anti-TB drugs has been reported [9]. This is likely to be caused by the mismanagement of pharmacological protocols. This scenario invokes the notion that testing for PZA resistance would be key to effective prescribing in TB, yet this is not routinely performed.

Despite its importance, the mechanism of action and resistance of PZA is not completely understood. Briefly, PZA is converted to POA by pyrazinamidase/nicotinamidase (PZAse) action in the mycobacterial cytoplasm. Once POA is produced it effluxes to the more acidic extracellular environment, where it is protonated. It then re-enters the cytoplasm where it reportedly acidifies the cytoplasm and interacts with different intracellular targets, resulting in cellular death [10–13].

Phenotypic Drug Susceptibility Testing (DST) for PZA is not included in routine testing for antimycobacterial drug resistance due to technical limitations specific to PZA. These limitations include a low critical concentration of PZA, and media alkalization by the inoculum, which is in conflict with the necessity to use a media pH close to neutrality [3, 14–17]. The way these tests should be ideally working is by indicating if the isolate is capable of surviving after exposure to PZA, in order to establish the optimal drug regimen to a particular patient. PZA *in vitro* testing however presents some intrinsic difficulties that have been delaying the standardization of its implementation and this has led to a lack of consensus [18].

The Wayne test and BACTEC MGIT 960 PZA (MGIT-PZA) are the phenotypic DSTs most commonly used to determine PZA susceptibility, although neither has been endorsed by the WHO. The Wayne test has a long turnaround time, and false-positive (resistance) reporting can occur due to subjective evaluation [15, 19]. On the other hand, MGIT-PZA has poor reproducibility, and a moderate to high rate of false resistance reporting due to a low critical concentration of PZA [6, 10]. Recently, a Microscopic Observation Drug Susceptibility (MODS) assay that incorporates the Wayne test (MODS-Wayne) has been described [20] and serves as a testing platform in the present study.

Analysis of the Mtbc genome to detect drug resistance is now encouraged because of its ease of use and a short time to completion. In the case of PZA this approach seeks to identify mutations in the *pncA* gene, which codifies for PZAse [5] However, the clinical utility of this method is reduced by the high variability of mutations along the *pncA* gene (no hot-spot is reported), the fact that not all mutations impair PZAse activity [7, 14, 21], and the lack of understanding of the relationship between each mutation and phenotypic resistance [6, 10]. Naturally-occurring Mtbc strains that express PZAse with defective enzymatic activity have been found to be totally or partially resistant to PZA [13]. In addition, some *pncA* mutations are not associated with phenotypic resistance, and phenotypic resistance can also occur in the absence of any mutations, indicating that additional factors are also involved.

Previous studies [8, 12] have demonstrated that the detection of POA in Mtbc culture medium is a good biomarker for PZA resistance: the absence of POA implies that no hydrolysis of PZA by PZAse is taking place and the isolate is, therefore, PZA resistant, whereas PZA susceptible strains produce POA under the same culture conditions. Measuring the
concentration of the metabolite POA in the culture medium could thus be considered as a proxy indicator of resistance [12].

Immunological detection is based on the generation of antibodies against a selected analyte. Molecules must be of a certain size for this to occur. Those smaller than 1500 Daltons are not immunogenic [11], and therefore a common strategy is to conjugate the analyte with a larger carrier molecule, forming a hapten-carrier construct. This can then be administered to a mammal in order to elicit the induction of specific antibodies that can then be used in immunological assays.

Low molecular weight analytes such as POA are not structurally compatible with conventional sandwich assays [9]. In 1973 the competitive ELISA was first described [5], whereby competition between the analyte and a synthetic version of the same molecule enabled the detection of small analytes. In this study, we demonstrate that a competitive indirect ELISA assay can detect POA under controlled conditions.

**Materials and methods**

**Chemicals, reagents and plasticware**

The following reagents were purchased from Thermo Scientific: BSA (bovine serum albumin in PBS, Imject BSA #77110), PMP (p-maleimidophenyl isocyanate, “LINKER” in this study, #28100), Imject mCKLH (mariculture keyhole limpet hemocyanin, 5 x 20 mg, in PBS, #77600), and 1-Step Ultra TMB (3,3’,5,5’-Tetramethylbenzidine, chromogenic ELISA substrate, #34028). An anti-rabbit horseradish peroxidase-labeled goat IgG was acquired from KPL (#074–1506). Traut’s reagent (2-Iminothiolane HCl) was acquired from ProteoChem (Utah, US, #M3103). POA derivative (5-hydroxyl-2-pyrazinecarboxylic acid, “POA.OH”) was synthesized by Shanghai Haoyuan ChemExpress, Inc. Zeba™ Spin Desalting Columns, 7K MWCO, 2 mL (Thermo, #89889) were used for purification steps. A microplate with hydrophilic/hydrophobic surface (Maxisorp 96-Well Plates, Thermo Scientific, #439454) was employed throughout the study. Young adult rabbits (New Zealand, white females, 2.5–3.0 kg) were acquired from the National Institute of Health (Lima, Peru).

**Instruments and buffers**

Plates were analyzed using the VersaMax microplate ELISA reader (Molecular Devices Co., Sunnyvale, CA, US). The following buffers were used: phosphate buffered saline (PBS, #21600010), composed of KCl 2.67 mM, KH2PO4 1.47 mM, NaCl 137.9 mM, Na2HPO4 8.1 mM; SEA BLOCK Blocking Buffer (steelhead salmon, i.e. *Oncorhynchus mykiss* serum in PBS, Thermo Scientific, #37527). Also, a “Traut’s solution” was prepared at a concentration of 54 μM in PBS buffer. Carbonate-bicarbonate coating buffer was acquired from Sigma (#C3041). A Nanodrop Spectrophotometer (Thermo Scientific #ND-2000) was used to assess the final concentration of constructs.

**Synthesis of constructs**

All the chemical constructs synthesized in this study are listed in Table 1 and their structural formulas are depicted in Fig 1.

First, synthesis of the injectable immunogen POA.OH linker KLH (PLK) was carried out exploiting the specific reactivity of PMP towards thiol groups. Briefly, 2 mg of carrier molecule mCKLH in 200 μL PBS buffer was incubated with 100 μL Traut’s solution (thiolation agent) for 90 minutes at room temperature, in constant rotation. Then, a 2 mL 7K MWCO Zeba column pre equilibrated with PBS was used to purify the precursor construct. This eluted
volume was diluted to 630 μL in PBS. 70 μL organic solvent DMSO containing 600 μg linker agent PMPI and 1960 μg POA.OH, which was previously incubated away from light for 3 hours in constant rotation, were then added to the mix. This final mixture was then incubated for 2 hours and purified using a 2 mL 7K MWCO Zeba column, and stored at 4˚C. The solution (approx. volume 700 μL) was mixed 1:1 with Freund’s adjuvant and used for immunization. Next, synthesis of POA.OH linker BSA (PLB) -used as competitive ELISA antigen- was carried out in a similar way as the synthesis of PLK. BSA was employed due to avoid undesired anti KLH activity in the icELISAs. Briefly, 2 mg BSA in 200 μL PBS buffer was incubated with 100 μL Traut’s solution for 90 minutes at room temperature, in constant rotation followed by purification as with PLK (see above). Similar to PLK, 70 μL DMSO containing 600 μg PMPI and 1960 μg POA.OH was added to give a total volume of 700 μL. The PLB final mixture was incubated and purified as described for PLK. 20 μL aliquots of the final elution were stored in PCR microtubes at -80˚C. Once an aliquot was thawed, it was stored at 4˚C and was not re-frozen. Finally, the Linker-BSA (LB), used as a routine preadsorption step to discard antibodies against the PMPI linker, was synthesized in a similar fashion as PLB but omitting POA.OH (i.e. 70 μL DMSO containing only 600 μg PMPI). 20 μL aliquots of the final elution were stored in PCR microtubes at -80˚C.

Production of rabbit polyclonal hyperimmune antibodies against POA

Rabbits were inoculated with the PLK construct (see Table 1) following the schedule outlined in Table 2. Ethical approval for the employment of rabbits was obtained from the Institutional Ethics Committee of the Universidad Peruana Cayetano Heredia, with registration code 59921. PLK was thoroughly mixed with Freund’s adjuvant in a 1:1 ratio until a thick emulsion was formed, and then administered using a subcutaneous route in divided doses of approximately 100 μg per site to reach a total delivery of 1 mg per individual at each time point. Ear vein bleeding was performed using a Vacutainer system and a butterfly needle. For terminal bleeding, rabbits were anesthetized with ketamine (10 mg/100 g body weight) and xylazine (1 mg/100 g body weight), and whole blood volumes (30 mL) were obtained by cardiac puncture using a 21G needle. Whole blood was collected into red cap Vacutainer® (BD Plus Serum tube) tubes which were mixed 6 times by inversion, allowed to rest for 1h, later transported to laboratory facilities, and then centrifuged at 1300 x g for 10 min, all these steps took place at room temperature. Supernatants (i.e. serum) were aliquoted in 0.2 ml tubes (50 μL per aliquot) and stored at – 80˚C. Hemolyzed samples were discarded.

Later, when icELISA analysis was performed, these serums underwent a routine preadsorption step in order to remove antibodies that were reactive against the linker moiety (PMPI) in the PLB. Serum was added to microwells pre-coated with LB and incubated overnight. Supernatants were collected and pooled, and this was used in all subsequent experiments.

### Table 1. Chemical constructs.

| Denomination | Components* | Detailed structure | Estimated synthesis time | Role |
|---------------|-------------|-------------------|-------------------------|------|
| PLK           | POA.OH-LINKER-KLH | 5-hydroxyl-2-pyrazinocarboxylic acid, p-maleimidophenyl isocyanate, 2-iminohiolane, mcKLH | 5h | Injectable immunogen |
| PLB           | POA.OH-LINKER-BSA | 5-hydroxyl-2-pyrazinocarboxylic acid, p-maleimidophenyl isocyanate, 2-iminohiolane, BSA | 5h | Competitive ELISA antigen |
| LB            | LNKER BSA    | p-maleimidophenyl isocyanate, 2-iminohiolane, BSA | 4h | Preadsorption step |

*For this study, p-maleimidophenyl isocyanate was denominated as “LINKER”.

[https://doi.org/10.1371/journal.pone.0241600.t001](https://doi.org/10.1371/journal.pone.0241600.t001)
**PLK**

*Injectable Immunogen*

~8 MDa

- **mcKLH**
- **PMPI** (214 Da)
- **POA** (124 Da)

**PLB**

*Competitive ELISA antigen*

66 kDa

- **BSA**
- **PMPI**
- **POA**

**LB**

*Preadsorption Step*

- **BSA**
- **PMPI**
Indirect competitive ELISA (icELISA)

An indirect competitive ELISA (icELISA) (Fig 2) was performed, where PLB served as a competitive antigen against POA. Microwells were coated by overnight incubation at 4˚C with PLB in 100 μL carbonate-bicarbonate buffer. The wells were washed, and PBS buffer spiked with different concentrations of POA (range 0.125 mg/mL–4 mg/mL) and final bleed (i.e. hyperimmune) antiserum were added. The plate was incubated for 1 h at room temperature, then washed. A peroxidase-labelled secondary antibody was added, and the plate was incubated for 1 h at room temperature. The colorimetric substrate was added then the plate was read using the VersaMax microplate ELISA reader (Molecular Devices Co., Sunnyvale, CA, US). Positive samples remained colorless, whereas negative samples underwent a color change (see Fig 2). POA concentrations were tested in duplicate, and a minimum of 20 assays were performed to confirm inter-assay consistency of the test (reproducibility). Antiserum, HRP, and PLB concentrations were standardized using a checkerboard titration.

The icELISA was performed using both pre-immunization and final bleed antiserum, and the ratio of reactivity was compared. The assay was also performed using PZA in place of POA, using the same range of concentrations, to test cross-reaction between the two compounds.

Microscopic Observation Drug Susceptibility (MODS)-Wayne assay and icELISA of MODS-Wayne culture medium

The MODS-Wayne assay [15] was integrated into the workflow with the aim of detecting POA in the assay's liquid culture medium. Ethical approval for the employed samples was obtained from the Institutional Ethics Committee of the Universidad Peruana Cayetano Heredia, with registration code 64196, which granted this study a Waiver of Ethical Approval Certificate. Briefly, sputum samples were decontaminated by mixing 1:1 with NaOH 2%, N-acetyl-L-cysteine 0.5%, and sodium citrate 1.45% in a 15 mL falcon tube, vortexed, and left for 15 min. 10 mL PBS was then added to neutralize the mixture, then samples were centrifuged at 3000 x g, 17˚C for 15 min. The supernatant was discarded and the pellet resuspended in 6 mL 7H9-OADC-PANTA (a 45:5:1 mixture of 7H9 [3.1 mL glycerol, 1.25 g BD Biosciences Bacto™ casitone, and 5.9 g BD Difco Middlebrook 7H9 Broth in 900 mL of ultrapure water], BD OADC enrichment and BD PANTA™ antibiotic mixture, respectively). A sample aliquot of 100 μL was inoculated into two wells, one that was designated a control well, and the other designated the PZA well. 6 days after growth was observed in both wells (visible cord formation),

Table 2. Immunization schedule.

| Event                                | Day  | Adjuvant               | Amount of immunogen |
|--------------------------------------|------|------------------------|---------------------|
| Pre immunization serum collection    | -10  | -                      | -                   |
| PLK Priming Injection                | 0    | Freund's Complete Adjuvant | 1 mg               |
| PLK Boosting Injection               | 14   | Freund's Incomplete Adjuvant | 1 mg               |
| PLK Boosting Injection/Ear vein bleeding | 28   | Freund's Incomplete Adjuvant | 1 mg               |
| PLK Boosting Injection               | 56   | Freund's Incomplete Adjuvant | 1 mg               |
| PLK Boosting Injection               | 84   | Freund's Incomplete Adjuvant | 1 mg               |
| Terminal bleeding/Start of Anti IgG ELISA | 98   | -                      | -                   |

https://doi.org/10.1371/journal.pone.0241600.t002
PZA was added to the PZA well at a final concentration of 800 $\mu$g/mL, and both wells were incubated for 3 further days. Then, freshly prepared ferrous ammonium sulfate (FAS) was added to both wells at a final concentration of 1%. Visualization of a pink complex was taken to indicate the presence of POA, and therefore a PZA sensitive strain, whereas absence of a color change was taken to indicate PZA resistance. The plate was immersed in a water bath at 90˚C for 30 minutes to sterilize the samples. 100 $\mu$L aliquots were then tested using the icE-LISA as described above. This was repeated 12 times using clinical samples positive for Mtb. Concordance between PZA resistance detected by the MODS-Wayne assay and by the icE-LISA was assessed.

In addition, wells containing 100 $\mu$L 7H9-OADC-PANTA were spiked with known concentrations of POA (range 0.125 mg/mL– 4mg/mL, as above). Ferrous ammonium sulfate (FAS) was added at a final concentration of 1%, and the icELISA was then performed. This was also repeated 12 times.

Results

PLK, PLB, and LB were generated and purified as described. Quantification using UV-vis spectrophotometry determined concentrations of 1.8 mg/mL, 1.79 mg/mL and 1.91 mg/mL, respectively, which were all considered to fall within an acceptable range according to technical manuals from several commercial conjugation kits. Due to technical constraints, additional chemical verification of constructs through techniques such as thin layer chromatography was...
not employed, but since commercially mature kits were used, and being these synthesis procedures well-established, reasonably analytical success was expected.

These constructs were diluted in PBS and optimum dilutions that elicited the maximum absorbance in the absence of the analyte (Amax) using the minimum amount of analyte capable of inhibiting 50% of the signal (IC50) were found to be 1:400 for LB, 1:5,000 for PLB, 1:4,500 for HRP (working concentration of 222 ng/mL) and an antiserum dilution of 1:50,000.

When the icELISA was performed using pre- and post-immunization serum the ratio of reactivity was 1:49, indicating a significant immune response at the programmed time point (98 days post immunization).

The parameters established during the optimization process described above generated the inhibition curve shown in Fig 3, with an IC50 of 1.16 mg/mL. The inhibition curve showed
reproducibility across many repetitions on separate days (Fig 4), demonstrating stability of the polyclonal antibodies and a strong immune reaction elicited by the antigens.

When the icELISA was performed using PZA as the analyte instead of POA, no inhibition reaction was observed at all (IC50 > 20 mg/mL). This indicates that no cross-reactivity between PZA and POA occurred and also indicated a successful synthesis procedure. Of the 12 clinical samples tested, eight (66.7%) were positive according to the MODS-Wayne assay (Table 3). When these supernatants were tested using the icELISA the ODs obtained were erratic and no coherent regression curve was produced (not shown). A comparison between MODS-Wayne results and ELISA-POA was therefore not possible (Table 3).

Similarly, when the icELISA was performed using 7H9 medium spiked with known concentrations of POA, instead of a sigmoidal inhibition curve a distorted, linear curve was obtained. This further supports the specificity of the icELISA for POA.

![Inhibition curves](https://doi.org/10.1371/journal.pone.0241600.g004)

Table 3. Tested samples.

| Number | Sample Code | MODS-Wayne Result | ELISA-POA Result |
|--------|-------------|--------------------|------------------|
| 1      | TBN64       | Positive           | Indeterminate    |
| 2      | TBN66       | Positive           | Indeterminate    |
| 3      | TBN67       | Positive           | Indeterminate    |
| 4      | TBN78       | Positive           | Indeterminate    |
| 5      | TBN018      | Positive           | Indeterminate    |
| 6      | TBN047      | Negative           | Indeterminate    |
| 7      | TBN052      | Negative           | Indeterminate    |
| 8      | TBN056      | Negative           | Indeterminate    |
| 9      | TBN077      | Negative           | Indeterminate    |
| 10     | TBN089      | Positive           | Indeterminate    |
| 11     | TBN090      | Positive           | Indeterminate    |
| 12     | TBN106      | Positive           | Indeterminate    |

A small cohort which included positive and negative MODS-Wayne samples was tested using the icELISA, with indeterminate results.
observed. Fig 5 shows that the ratio between the sample with analyte bound versus sample with no analyte present ($B/B_0$) surpassed 1 at low concentrations of POA, a technically impossible result, while crude ODs were significant (OD > 0.1).

Following this finding, we sought to establish whether these distorted results were due to the presence of the culture medium or the FAS. We repeated the icELISA using known concentrations of POA in PBS and included FAS (0.1% or 1%). The inhibition curve generated was similar to the curve shown in Fig 3.

**Discussion**

In this study, we have shown that it is possible to reliably induce polyclonal a hyperimmune antibodies in response to POA, a small molecule, in a mammalian model by haptenization. Similar findings have previously been achieved by other groups using small analytes such as proline (115 g/mol) [22]. We were then able to detect commercial POA in ultrapure water or PBS buffer using our icELISA, which consistently generated a specific competitive inhibition curve with an IC50 of 1.16 mg/mL (9.35 mM POA).

When designing an icELISA, critical aspects of immunogen efficiency to consider include establishing the correct exposure of antigenic determinants to ensure specificity and the length of the spacer arm: an arm that is too short may become masked by the carrier surface, whereas a long spacer arm could create heterogeneous tertiary structures, diluting its immunogenic potential [23]. In the present study, the POA derivative 5-hydroxyl-2-pyrazinecarboxylic acid was the only one that was commercially available, which was a starting constraint for the
study. For that reason, only conjugation strategies capable of using the hydroxyl group were considered, and PMPI was chosen as the linker. This allowed us to expose the carboxyl group that differentiates it from PZA and enabled us to generate a specific immunoassay. Nevertheless, despite these limitations, the IC50 achieved by our assay was high (1.16 mg/mL) compared to other competitive immunoassay studies using small molecules such as aflatoxin g1 (278.321 g/mol, IC50: 17.18 ng/mL) [24].

The Wayne assay has been estimated as having a sensitivity of 0.5 mM POA, and the quantitative version as having a sensitivity of 0.05 mM [8], one and two orders of magnitude greater than the platform described in the present study, respectively. It is possible that the icELISA detection limit could be lowered by carrying out some additional optimization. Pioneering studies using in vivo models to generate antibodies typically used large numbers of immunized animals, which enabled the testing of a range of different routes of administration, immunization schedules, and adjuvants. This allowed for largescale screening of hyperimmunized sera [25], maximizing the probability of finding an individual or individuals with excellent response. This was not the case for our study, which was limited by our staff availability, facilities, and access to reagents. This method of trial and error could in future studies surpass this limitation and arrive at an optimal protocol for the generation in rabbits of polyclonal antibodies with very high affinity, and with an IC50 in the range of nanograms per milliliter.

Overcoming the challenges in incorporating MODS culture medium into the icELISA assay would represent a significant step in the development of this assay and move towards a clinically useful test for the detection of PZA resistance in clinical strains. The MODS-Wayne assay is based upon attaining growth of Mtb in liquid culture medium (mean time to positivity 7 days) and, once growth is visible, the addition of PZA. Currently, the MODS-Wayne assay requires a further three days of bacterial growth before FAS can be added and the strain’s sensitivity to PZA revealed via the presence or absence of a color change. The icELISA would replace this final step, and thereby shorten the process by two days. This could be clinically important to patients who are being treated with an ineffective drug regimen.

The present study demonstrates that detection of POA using a competitive ELISA is possible, and serves as a primer to identify technical challenges in assay design and elucidate which novel technologies could be applied to solve them. Further work to optimize the assay is needed before a commercial translatable system can be developed. Routine microbiological tests should not be cumbersome, too expensive, nor impractical. Emerging ultra-sensitive applications such as immuno-PCR could integrate very well into our workflow and surpass all mentioned obstacles so far [27]; or, improved final step amplified detection strategies such as a biotin streptavidin system could be incorporated [28]. Upcoming cost/benefit analyses will give us more insight in this regard.

Supporting information

S1 Table. Curve readings. ODs conforming POA curve. (XLSX)
S2 Table. **Antibody titration.** ODs obtained in the titration of the antibody when PLB was added to the bottom of the well.

(XLSX)

**Acknowledgments**

We would like to thank all fellow workers, colleagues, and researchers who supported us as a team including but not limited to, Edith Málaga, Inés Cabello, Holger Mayta PhD, among others.

**Author Contributions**

**Conceptualization:** Edgar A. Florentini.

**Formal analysis:** Roberto Alcántara, Danni Kirwan.

**Funding acquisition:** Mirko Zimic, Patricia Sheen.

**Investigation:** Edgar A. Florentini, Noelia Angulo, Elisa Roncal, Ricardo Antiparra, Emily Toscano, Katherine Vallejos, Mirko Zimic.

**Methodology:** Roberto Alcántara, Elisa Roncal, Ricardo Antiparra, Emily Toscano, Katherine Vallejos, Mirko Zimic.

**Project administration:** Robert H. Gilman, Mirko Zimic, Patricia Sheen.

**Resources:** Robert H. Gilman.

**Supervision:** Robert H. Gilman, Roberto Alcántara, Mirko Zimic, Patricia Sheen.

**Validation:** Noelia Angulo.

**Writing – original draft:** Edgar A. Florentini, Noelia Angulo.

**Writing – review & editing:** Edgar A. Florentini, Danni Kirwan, Mirko Zimic.

**References**

1. WHO. Global Tuberculosis Report. Geneva: World Health Organization, 2018.

2. Girum T, Muktar E, Lentiro K, Wondiyi H, Shewangizaw M. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 2018; 4:5. Epub 2018/06/27. https://doi.org/10.1186/s40794-018-0065-5 PMID: 29942536; PubMed Central PMCID: PMC6000958.

3. Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of Pyrazinamide Action and Resistance. Microbiol Spectr. 2013; 2(4):1–12. Epub 2013/01/01. https://doi.org/10.1128/microbiolspec.MGM2-0023-2013 PMID: 25530919; PubMed Central PMCID: PMC4268777.

4. Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, et al. Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infect Dis. 2015; 1(5):203–14. Epub 2015/06/19. https://doi.org/10.1021/id500028m PMID: 26086040; PubMed Central PMCID: PMC4467917.

5. Belanger L, Sylvestre C, Dufour D. Enzyme-linked immunoassay for alpha-fetoprotein by competitive and sandwich procedures. Clin Chim Acta. 1973; 48(1):15–8. Epub 1973/09/28. https://doi.org/10.1016/0009-8981(73)90211-8 PMID: 4201034.

6. Demers AM, Venter A, Friedrich SO, Rojas-Ponce G, Mapamba D, Jugheili L, et al. Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the BACTEC MGIT 960 System. J Clin Microbiol. 2016; 54(5):1276–81. Epub 2016/02/26. https://doi.org/10.1128/JCM.03162-15 PMID: 26812781; PubMed Central PMCID: PMC4844746.

7. Li H, Chen J, Zhou M, Geng X, Yu J, Wang W, et al. Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated
gene-to-protein function approach. J Clin Microbiol. 2014; 52(1):260–7. Epub 2013/11/15. https://doi.org/10.1128/JCM.02285-13 PMID: 24226918; PubMed Central PMCID: PMC3911477.

8. Meinzen C, Proano A, Gilman RH, Caviedes L, Coronel J, Zimic M, et al. A quantitative adaptation of the Wayne test for pyrazinamide resistance. Tuberculosis (Edinb). 2016; 99:41–6. Epub 2016/07/28. https://doi.org/10.1016/j.tube.2016.03.011 PMID: 27450003.

9. Darwish IA. Immunoassay Methods and their Applications in Pharmaceutical Analysis: Basic Methodology and Recent Advances. Int J Biomed Sci. 2006; 2(3):217–35. Epub 2006/09/01. PMID: 23674985; PubMed Central PMCID: PMC3614608.

10. Li D, Hu Y, Werngren J, Mansjo M, Zheng X, Drobniewski F, et al. Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China. Antimicrob Agents Chemother. 2016; 60(9):5159–66. Epub 2016/06/15. https://doi.org/10.1128/AAC.02687-15 PMID: 27297481; PubMed Central PMCID: PMC4997820.

11. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 2002; 51(1):42–9. Epub 2002/01/22. https://doi.org/10.1099/0022-1317-51-1-42 PMID: 11800471.

12. Zimic M, Fuentes P, Gilman RH, Gutierrez AH, Kirwan D, Sheen P. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis (Edinb). 2012; 92(1):84–91. Epub 2011/10/19. https://doi.org/10.1016/j.tube.2011.09.002 PMID: 22004792; PubMed Central PMCID: PMC3269536.

13. Konno K, Feldmann FM, McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 1967; 95(3):461–9. Epub 1967/03/01. https://doi.org/10.1164/arrd.1967.95.3.461 PMID: 4225184.

14. Miotti P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio. 2014; 5(5):e01819–14. Epub 2014/10/23. https://doi.org/10.1128/mBio.01819-14 PMID: 25336456; PubMed Central PMCID: PMC4212837.

15. Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother. 2011; 55(10):4499–505. Epub 2011/07/20. https://doi.org/10.1128/AAC.00630-11 PMID: 21768515; PubMed Central PMCID: PMC3186960.

16. Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother. 1988; 32(7):1002–4. Epub 1988/07/01. https://doi.org/10.1128/aac.32.7.1002 PMID: 3142340; PubMed Central PMCID: PMC172333.

17. Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L. Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. J Clin Microbiol. 2013; 51(1):291–4. Epub 2012/10/27. https://doi.org/10.1128/JCM.01838-12 PMID: 23100351; PubMed Central PMCID: PMC3536208.

18. Horne DJ, Pinto LM, Arentz M, Lin SY, Desmond E, Flores LL, et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol. 2013; 51(2):393–401. Epub 2012/11/16. https://doi.org/10.1128/JCM.02724-12 PMID: 23152548; PubMed Central PMCID: PMC3553871.

19. Ramirez-Busby SM, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015; 59(9):5267–77. Epub 2015/06/17. https://doi.org/10.1128/AAC.00204-15 PMID: 26077261; PubMed Central PMCID: PMC4538510.

20. Alcantara R, Fuentes P, Antiparra R, Santos M, Gilman RH, Kirwan DE, et al. MODS-Wayne, a Colorimetric Adaptation of the Microscopic-Observation Drug Susceptibility (MODS) Assay for Detection of Mycobacterium tuberculosis Pyrazinamide Resistance from Sputum Samples. J Clin Microbiol. 2019; 57(2). Epub 2018/11/16. https://doi.org/10.1128/JCM.01162-18 PMID: 30429257; PubMed Central PMCID: PMC6355525.

21. Zhou M, Geng X, Chen J, Wang X, Wang D, Deng J, et al. Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One. 2011; 6(11):e27654. Epub 2011/11/22. https://doi.org/10.1371/journal.pone.0027654 PMID: 22102918; PubMed Central PMCID: PMC3213173.

22. Nishikawa S, Ishiguro S, Tamai M. Localization of proline-like immunoreactivity in young rat retinal neurons. Curr Eye Res. 1996; 15(9):951–7. Epub 1996/09/01. https://doi.org/10.3109/02713689609017640 PMID: 8921218.
23. Marco MP GS, Hammock BD. Immunoc hemical technique s for environ mental analysis II. Antibody pro-
duction and immunoassa y developme nt. Trends in Analytical Chem istry. 1995; 14(8):415–425(8):10. h
https://doi.org/10.1016/0165-9936(95)90920-I
24. Li P, Zhou Q, Wang T, Zhou H, Zhang W, Ding X, et al. Development of an Enzyme-Linked Immunosor-
bell Assay Method Specific for the Detection of G-Group Aflatoxins. Toxins (Basel). 2015; 8(1). Epub 2016/01/06. h
https://doi.org/10.3390/toxins8010005 PMID: 26729164; PubMed Central PMCID: PMC4728527.
25. Vallejo RP, Bogus ER, Mumma RO. Effects of hapten structure and bridging groups on antisera speci-
icity in parathion immunoassay development. J Agric Food Chem. 1982; 30(3):572–80. Epub 1982/05/01. h
https://doi.org/10.1021/jf00111a040 PMID: 7096810.
26. Tang X, Li X, Li P, Zhang Q, Li R, Zhang W, et al. Development and application of an immunoaffinity col-
umn enzyme immunoassay for mycotoxin zearalenone in complicated samples. PLoS One. 2014; 9(1): e85606. Epub 2014/01/28. h
https://doi.org/10.1371/journal.pone.0085606 PMID: 24465616; PubMed Central PMCID: PMC3894983.
27. Malou N, Raoult D. Immuno-PCR: a promising ultrasensitive diagnostic method to detect antigens and 
antibodies. Trends Microbiol. 2011; 19(6):295–302. Epub 2011/04/12. h
https://doi.org/10.1016/j.tim.2011.03.004 PMID: 21478019.
28. Wang L, Zhang Y, Gao X, Duan Z, Wang S. Determination of chloramphenicol residues in milk by 
enzyme-linked immunosorbent assay: improvement by biotin-streptavidin-amplified system. J Agric 
Food Chem. 2010; 58(6):3265–70. Epub 2010/03/03. h
https://doi.org/10.1021/jf903940h PMID: 20192212.